Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Actinic Keratoses Clear all

Not listed Phase 4 Interventional

Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face

NCT06745999

View directory record Official record

Conditions: Actinic Keratoses
Interventions: Ameluz 10% Topical Gel, Red Light PDT, Cryotherapy; Drug · Device · Procedure
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older

Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: East Windsor, New Jersey

Source: ClinicalTrials.gov public record

Updated Dec 23, 2024 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1 Interventional

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367

View directory record Official record

Conditions: Actinic Keratosis
Interventions: Ingenol Mebutate 0.015%; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Dec 30, 2013 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1 Interventional

Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2

NCT00659893

View directory record Official record

Conditions: Actinic Keratosis
Interventions: PEP005 Topical gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Tucson, Arizona • San Diego, California • Orange Park, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Sep 13, 2015 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 3 Interventional Results available

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

NCT03200912

View directory record Official record

Conditions: ACTINIC KERATOSIS
Interventions: Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 95 Years

Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more

Source: ClinicalTrials.gov public record

Updated Jan 13, 2020 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 3 Interventional

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

NCT05078827

View directory record Official record

Conditions: Actinic Keratoses
Interventions: Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India; Drug
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older

Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more

Source: ClinicalTrials.gov public record

Updated Mar 13, 2023 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 3 Interventional

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

NCT03826550

View directory record Official record

Conditions: Actinic Keratoses
Interventions: Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo; Drug · Other
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older

Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 24
States / cities: Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more

Source: ClinicalTrials.gov public record

Updated Jan 31, 2019 · Synced May 21, 2026, 6:33 PM EDT

Completed No phase listed Observational Results available

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

NCT05260073

View directory record Official record

Conditions: Keratosis, Actinic
Interventions: Tirbanibulin; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years and older

Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Source: ClinicalTrials.gov public record

Updated Sep 19, 2024 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 4 Interventional

Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times

NCT02622594

View directory record Official record

Conditions: Actinic Keratoses
Interventions: Aminolevulinic Acid (ALA), Environ Cosmetic Roller, BLU-U IIlluminator; Drug · Device
Lead sponsor: Dermatology, Laser & Vein Specialists of the Carolinas; Other
Eligibility: 18 Years and older

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlotte, North Carolina

Source: ClinicalTrials.gov public record

Updated Jul 18, 2017 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804

View directory record Official record

Conditions: Actinic Keratosis
Interventions: Diclofenac sodium, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older

Enrollment: 492 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more

Source: ClinicalTrials.gov public record

Updated May 4, 2017 · Synced May 21, 2026, 6:33 PM EDT

Recruiting Not applicable Interventional

Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia

NCT03906253

View directory record Official record

Conditions: Actinic Keratoses, Aging, Non-Melanoma Skin Cancer
Interventions: Fractionated Laser Resurfacing; Device
Lead sponsor: Wright State University; Other
Eligibility: 60 Years and older

Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Dayton, Ohio

Source: ClinicalTrials.gov public record

Updated Mar 24, 2025 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

NCT00742391

View directory record Official record

Conditions: Actinic Keratoses
Interventions: PEP005 (ingenol mebutate) Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older

Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Mesa, Arizona • Denver, Colorado • Kissimmee, Florida + 14 more

Source: ClinicalTrials.gov public record

Updated Mar 5, 2015 · Synced May 21, 2026, 6:33 PM EDT

Terminated No phase listed Observational

Comparing Immune Responses to Topical Imiquimod

NCT04809662

View directory record Official record

Conditions: Actinic Keratoses
Interventions: Imiquimod; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 85 Years

Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Source: ClinicalTrials.gov public record

Updated Nov 6, 2024 · Synced May 21, 2026, 6:33 PM EDT

Completed Not applicable Interventional Accepts healthy volunteers

Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

NCT01905891

View directory record Official record

Conditions: Actinic Keratosis, Squamous Cell Carcinoma
Interventions: Superficial shave biopsy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years

Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Source: ClinicalTrials.gov public record

Updated Nov 18, 2014 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 4 Interventional Results available

Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

NCT02446223

View directory record Official record

Conditions: Actinic Keratosis
Interventions: Inggenol Mebutate 0.015%; Drug
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 18 Years and older

Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Source: ClinicalTrials.gov public record

Updated Sep 5, 2019 · Synced May 21, 2026, 6:33 PM EDT

Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

NCT07144852

View directory record Official record

Conditions: Actinic Keratosis
Interventions: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.; Drug · Other · Device
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 17 more

Source: ClinicalTrials.gov public record

Updated Apr 21, 2026 · Synced May 21, 2026, 6:33 PM EDT

Completed Not applicable Interventional

A Photodynamic Therapy for Treatment of Actinic Keratoses

NCT00558688

View directory record Official record

Conditions: Actinic Keratoses
Interventions: Photodynamic therapy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 90 Years

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Source: ClinicalTrials.gov public record

Updated Dec 5, 2021 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 3 Interventional Results available

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

NCT01686152

View directory record Official record

Conditions: Actinic Keratosis
Interventions: Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older

Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Tucson, Arizona • Encino, California • Los Angeles, California + 20 more

Source: ClinicalTrials.gov public record

Updated Nov 23, 2020 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 4 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

NCT00115154

View directory record Official record

Conditions: Keratosis
Interventions: Aldara (imiquimod) cream, 5%; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more

Source: ClinicalTrials.gov public record

Updated Feb 18, 2007 · Synced May 21, 2026, 6:33 PM EDT

Completed Not applicable Interventional Results available

The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy

NCT02594644

View directory record Official record

Conditions: Keratosis, Actinic
Interventions: Microneedle Roller, Aminolevulinic Acid, Blue Light; Device · Drug · Radiation
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older

Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Source: ClinicalTrials.gov public record

Updated Nov 28, 2018 · Synced May 21, 2026, 6:33 PM EDT

Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395

View directory record Official record

Conditions: Keratosis, Actinic
Interventions: MAL Cream, Vehicle cream; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older

Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 52
States / cities: Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more

Source: ClinicalTrials.gov public record

Updated Oct 9, 2023 · Synced May 21, 2026, 6:33 PM EDT

Completed No phase listed Observational

Twelve Month Follow-Up of CP0108

NCT02209012

View directory record Official record

Conditions: Actinic Keratosis
Interventions: Aminolevulinic Acid (ALA), Topical Solution Vehicle, BLU-U Blue Light Photodynamic Therapy Illuminator; Drug · Device
Lead sponsor: DUSA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Fremont, California • San Diego, California • Aventura, Florida + 10 more

Source: ClinicalTrials.gov public record

Updated Sep 22, 2016 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 2 Interventional

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

NCT00335179

View directory record Official record

Conditions: Actinic Keratosis
Interventions: Aldara (imiquimod 5% cream), Vehicle cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Loma Linda, California

Source: ClinicalTrials.gov public record

Updated Jul 22, 2010 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1 Interventional Results available

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

NCT04319159

View directory record Official record

Conditions: Actinic Keratoses
Interventions: BF-200 ALA and red light LED lamp; Combination Product
Lead sponsor: Biofrontera Bioscience GmbH; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Source: ClinicalTrials.gov public record

Updated Nov 10, 2021 · Synced May 21, 2026, 6:33 PM EDT

Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Photodynamic Therapy Incubation Times for Actinic Keratosis

NCT03066843

View directory record Official record

Conditions: Actinic Keratoses
Interventions: ALA (5-aminolevulinic acid), Blue light therapy; Drug · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Source: ClinicalTrials.gov public record

Updated Jan 30, 2025 · Synced May 21, 2026, 6:33 PM EDT